Results 91 to 100 of about 3,831 (231)

Genomic analysis and antimicrobial activity of β-lactam/β-lactamase inhibitors and other agents against KPC-producing Klebsiella pneumoniae clinical isolates from Brazilian hospitals

Scientific Reports, 2023
Carbapenem-resistant Klebsiella pneumoniae (CRKP) are highly disseminated worldwide, and isolates co-resistant to other antimicrobial agents pose a threat to effective antimicrobial therapy. Therefore, evaluation of novel antimicrobial drugs is needed to
Carlos Henrique Camargo, Amanda Yaeko Yamada, Andreia Rodrigues de Souza, Marcos Paulo Vieira Cunha, Pedro Smith Pereira Ferraro, Claudio Tavares Sacchi, Marlon Benedito dos Santos, Karoline Rodrigues Campos, Monique Ribeiro Tiba-Casas, Maristela Pinheiro Freire, Pasqual Barretti   +10 more
doaj   +1 more source

A Review of β‐Lactamase Inhibitors in Clinical Use and Development: Mechanisms, Spectrum, and Therapeutic Applications

International Journal of Microbiology, Volume 2026, Issue 1, 2026.
β‐Lactam antibiotics have long served as a cornerstone for treating bacterial infections. However, their widespread and often indiscriminate use has fueled the emergence of multidrug‐resistant Gram‐negative pathogens, primarily through the production and dissemination of β‐lactamase enzymes.
Mohammad Javad Roustaye Gourabi, Anita Nikoo, Bita Khanbabaei, Masoud Kargar, Amirhossein Fayyazi, Seyyed Mohammad Javad Mousavi, Amirhossein Aghdaee, Ali Hashemi, Javad Yasbolaghi Sharahi, Swaran J. S. Flora   +9 more
wiley   +1 more source

Mechanistic basis for inhibition of the extended‐spectrum β‐lactamase GES‐1 by enmetazobactam and tazobactam

FEBS Letters, Volume 599, Issue 22, Page 3284-3300, November 2025.
Antimicrobial resistance (AMR) is of huge importance, resulting in over 1 million deaths each year. Here, we describe how a new drug, enmetazobactam, designed to help fight resistant bacterial diseases, inhibits a key enzyme (GES‐1) responsible for AMR. Our data show it is a more potent inhibitor than the related tazobactam, with high‐level computation
Michael Beer, Philip Hinchliffe, Marko Hanževački, Christopher R. Bethel, Catherine L. Tooke, Marc W. Van der Kamp, Krisztina M. Papp‐Wallace, Robert A. Bonomo, Stuart Shapiro, Adrian J. Mulholland, James Spencer   +10 more
wiley   +1 more source

Aztreonam Combinations with Avibactam, Relebactam, and Vaborbactam as Treatment for New Delhi Metallo-β-Lactamase-Producing Enterobacterales Infections—In Vitro Susceptibility Testing

Pharmaceuticals
Antimicrobial resistance is a major global health issue. Metallo-β-lactamases (MBL), in particular, are problematic because they can inactivate all classes of β-lactams except aztreonam.
Małgorzata Brauncajs, Filip Bielec, Marlena Malinowska, Dorota Pastuszak-Lewandoska   +3 more
doaj   +1 more source

Development of an HPLC Method for the Determination of Meropenem/Vaborbactam in Biological and Aqueous Matrixes

Journal of Chromatographic Science, 2020
Abstract A HPLC method was developed and validated to analyze meropenem and vaborbactam simultaneously in murine plasma and saline matrixes. A 60-μL volume of extracted sample was injected onto a 5-μm BDS Phenyl-Hypersil C18 reversed-phase column and analyzed with a UV detector set at 298 nm for the first 4.9 min and switched to 240 nm ...
Christina A, Sutherland, David P, Nicolau   +1 more
openaire   +2 more sources

Antibiotic Resistance: A Genetic and Physiological Perspective

MedComm, Volume 6, Issue 11, November 2025.
The development of resistance to antimicrobials and their historical progression are depicted in this graphic. It draws attention to important biochemical, physiological, and genetic factors that contribute to AMR, such as the transmission of genes, the development of biofilms, and the inactivation of antibiotics.
Rania G. Elbaiomy, Ahmed H. El‐Sappah, Rong Guo, Xiaoling Luo, Shiyuan Deng, Meifang Du, Xiaohong Jian, Mohammed Bakeer, Zaixin Li, Zhi Zhang   +9 more
wiley   +1 more source

Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem‐resistant Enterobacteriaceae [PDF]

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2018
Vaborbactam (VAB; formerly RPX7009) is a novel beta‐lactamase inhibitor based on a cyclic boronic acid pharmacophore with potent inhibitory activity against Ambler class A and C beta‐lactamases. It has been co‐formulated with meropenem to restore its activity against Klebsiella pneumoniae carbapenemases (KPC).
Sarah Christina Jane Jorgensen, Michael Joseph Rybak   +1 more
openaire   +2 more sources

Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment

, 2018
Vaborbactam is a member of a new class of β-lactamase inhibitors with inhibitory activity against serine carbapenemases (e.g., Klebsiella pneumoniae carbapenemase) that has been developed in combination with meropenem.
Michael N. Dudley, Christopher M. Rubino, Jeffery S. Loutit, Sujata M. Bhavnani, Brooke Lohse, David C. Griffith   +5 more
core   +1 more source

Effect of Colistin, Fosfomycin and Meropenem/Vaborbactam on Carbapenem-Resistant Enterobacterales in Egypt: A Cross-Sectional Study

Infection and Drug Resistance, 2022
Raghdaa Shrief,1 Amira H El-Ashry,2 Rasha Mahmoud,3 Rasha El-Mahdy2 1Medical Microbiology and Immunology Department, Faculty of Medicine, Damietta University, Damietta, Egypt; 2Medical Microbiology and Immunology Department, Faculty of Medicine, Mansoura
Shrief R, El-Ashry AH, Mahmoud R, El-Mahdy R   +3 more
doaj  

Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections [PDF]

Clinical Infectious Diseases, 2019
AbstractTwenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirty-day clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days.
Ryan K, Shields, Erin K, McCreary, Rachel V, Marini, Ellen G, Kline, Chelsea E, Jones, Binghua, Hao, Liang, Chen, Barry N, Kreiswirth, Yohei, Doi, Cornelius J, Clancy, M Hong, Nguyen   +10 more
openaire   +2 more sources